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Rationale: The study of genetic modifiers in cystic fibrosis (CF) lung
disease requires rigorous phenotyping. One type of genetic associa-
tion study design compares polymorphisms in patients at extremes
of phenotype, requiring accurate classification of pulmonary disease
at varying ages.
Objective: To evaluate approaches to quantify severity of pulmonary
disease and their ability to discriminate between patients with CF
at the extremes of phenotype.
Methods: F508 homozygotes (n  828) were initially classified as
“severe” (approximate lowest quartile of FEV1 (% pred) for age, 8–25
yr) or “mild” disease (highest quartile of FEV1 for age,  15 yr). FEV1
measurements from the 5 yr before enrollment (total  18,501
measurements; average 23 per subject) were analyzed with mixed
models, and patient-specific estimates of FEV1 (% pred) at ages 5,
10, 15, 20, and 25 yr and slope of FEV1 versus age were examined
for their ability to discriminate between groups using receiver op-
erating characteristics (ROC) curve areas.
Results: Logistic regression of severity group on mixed model (em-
pirical Bayes) estimates of intercept and slope of FEV1 (% pred)
versus age discriminated better than did classification using FEV1
slope alone (ROC area  0.995 vs. 0.821) and was equivalent to
using estimated FEV1 at 20 yr of age as a single discriminator. The
estimated survival percentile from a joint survival/longitudinal
model provided equally good classification (ROC area  0.994).
Conclusions: In CF, estimated FEV1 (% pred) at 20 yr of age and the
estimated survival percentile are useful indices of pulmonary disease
severity.
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Cystic fibrosis (CF) is an autosomal recessive genetic disease
caused by mutations in the cystic fibrosis transmembrane con-
ductance regulator (CFTR) gene. Because most patients with CF
develop progressive pulmonary disease, measures of pulmonary
involvement, in particular FEV1, have been used as markers of
disease severity and to predict survival (1–3). However, consider-
able heterogeneity exists in prognosis and severity, even among
patients of the same genotype, suggesting that genetic modifiers
may play a role (4). The study of gene modifiers in monogenic
disorders requires rigorous phenotyping, and inadequate charac-
terization of the phenotype is a well-recognized limitation of
case-control genetic association studies (5–8). In CF, pulmonary
phenotyping is complex because the progression of lung disease
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is likely multifactorial and is multiphasic or nonlinear for some
patients (9, 10).
One specific type of case-control genetic association study
design compares patients at the extremes of phenotype (i.e.,
those with severe versus mild disease) because it provides addi-
tional power to detect gene modifiers (11). In such studies, it is
particularly important to be able to accurately identify patients
at the extremes of phenotype. In this article, we investigate
approaches to classifying severity of disease when longitudinal
lung function measures are available and compare them using
data from the Gene Modifier Study (GMS), a large, multicenter
study of genetic modifiers of CF lung disease (12). The goal of
the GMS is to examine the association of genetic polymorphisms
with pulmonary phenotype in F508 homozygotes by comparing
patients with “severe” versus “mild” pulmonary disease.
METHODS
Design and Enrollment Criteria in the GMS
Patients were initially enrolled into “severe” or “mild’ groups based
on current age and most recent FEV1 (% pred) while they were clinically
stable (12). The severe group included patients 8–25 yr of age, and the
mild group was divided into young and older subgroups (15–28 and 
29 yr of age, respectively). Enrollment by severity group was based on
age-specific cutoff values for FEV1 (% pred; see online supplement),
derived approximately from quartiles of lung function for patients 
34 yr of age in the U.S. Cystic Fibrosis Foundation Patient Registry
(13). Patients  34 yr of age were considered “mild” regardless of their
FEV1, on the basis of survival. All available spirometric data in the
previous 5 yr for each patient were collected, including pre- and post-
bronchodilator values, regardless of the patient’s status with respect to
acute illnesses. Analyses used the prebronchodilator value if available
(97% of measurements). Otherwise, the post-bronchodilator value was
used. Percent predicted values for spirometry measurements were cal-
culated using Knudson equations (14).
Characterization of Longitudinal Patterns of FEV1 in
Individual Patients
Longitudinal FEV1 data were analyzed using a mixed model, assuming
that the mean FEV1 (% pred) follows a linear regression versus time
for each patient with random patient-specific slope and intercept, with
a separate population regression line for each of the three severity
groups (Appendix 1). The mixed model provided estimates of the mean
intercept and slope by severity group and estimates of patient-specific
slopes and intercepts (empirical Bayes estimates).
We first reexamined the initial classification of each patient, which
was based on their single FEV1 at enrollment, by analyzing all longitudi-
nal data. Mixed model estimates of individual patients’ intercepts (FEV1
at age of birth) and slopes (rates of FEV1 decline), obtained from the
mixed linear model fit to data from all patients, were used to estimate
the true underlying FEV1 at enrollment for each subject. A logistic
regression of disease group (severe vs. mild) on age and estimated FEV1
at enrollment was fit, and patients for whom the predicted probability of
being in their initial group was less than 0.90 were identified as outliers
and excluded from further analyses. This was done using all FEV1
values and by using the maximal yearly value for each patient. This
resulted in a final dataset with 802 subjects (256 severe, 304 young mild,
242 older mild) with a total of 18,501 FEV1 measurements.
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Figure 1. FEV1 criteria (boundaries) used to enroll patients
as severe (8–25 yr of age) or mild ( 15 yr of age) in the
Gene Modifier Study. Specific cut-off values are provided
in the online supplement. The dotted line shows median
FEV1 (% pred) for age for patients with cystic fibrosis (CF)
who were 12–24 yr of age (average of male and female
values), using CF-specific reference standards (22).
Receiver operating characteristics (ROC) curves (15) were used to
evaluate and compare several patient-specific summary indices to assess
which were best at discriminating between mild and severe groups. The
summary indices included mixed model and least squares (LS) estimates
of patient-specific rates of decline in FEV1 (% pred) and levels of FEV1
(% pred) at 5–25 yr of age.
We predicted age at death based on a model relating survival to
longitudinal lung function, using parameters estimated from an analysis
of an external dataset of n  188 homozygous F508 patients (2). This
estimate of age at death was also evaluated as a severity measure.
Analyses were performed using SAS version 9.1 (16). Data are
presented as mean  SD. Between-group comparisons were made using
2 tests for categorical variables and using one-way analysis of variance
for continuous variables.
RESULTS
Screening for Outliers and Characterization of
Severity Groups
The age-specific boundaries of FEV1 (% pred) at enrollment,
used for initial classification by severity, are shown in Figure 1.
The specific cutoffs used at each age are provided in the online
supplement.
Mixed model estimates of slope and intercept (at birth; i.e.,
age, 0 yr) of the regression of FEV1 (% pred) versus age were
used to estimate the level of FEV1 at the age of enrollment for
each patient and at other fixed ages (e.g., 15, 10, 15, 20, and 25 yr).
In Figure 2, the estimated FEV1 (% pred) values at enrollment
(obtained from an analysis of all FEV1 values) are plotted against
age of enrollment for the 820 patients. Patients identified as
outliers based on logistic regression of severity group on age
and estimated FEV1 (% pred) at enrollment (see Methods) are
identified as open circles (n  12). Similar analysis using only
the best yearly FEV1 values identified an additional six patients
as outliers, labeled as open triangles in the figure. These 18
patients were excluded from further analyses reported herein.
Table 1 summarizes demographic and clinical information at
the time of enrollment and the number of FEV1 measurements
obtained per subject in the 5 yr before enrollment for the 802
patients separated into severe, young mild, and older mild
groups. Summary indices describing the individual patients’ re-
gression lines of FEV1 (% pred) versus age are also provided,
including the patient-specific slope and estimated FEV1 (% pred)
at 15 and 20 yr of age. The difference between mean predicted
levels of FEV1 (% pred) at 15 and 20 yr of age within a group
equals the mean slope multiplied by 5 yr. Significant differences
between all three groups were found in terms of FEV1 decline
and estimated levels of FEV1 at 15 and 20 yr of age, with the
severe and young mild groups being most and least severe, re-
spectively, and the older mild group having values intermediate
between the other two groups.
Ability of Measures of Disease Severity to Discriminate
between Extremes of Phenotype
Patient-specific summary measures, derived from the patients’
longitudinal data, were evaluated in their ability to distinguish
between severe versus mild groups. Discriminating ability was
ascertained using the area under the ROC curve, which plots
sensitivity versus 1-specificity of the index as the threshold value
(cutpoint) used for classification is varied. The ROC area ranges
Figure 2. Estimated FEV1 (% pred) at age at enrollment versus age at
enrollment. The FEV1 (% pred) values were estimated based on a mixed
model analysis of all available data from each patient (see text and
Appendix 1). Open circles and triangles represent patients identified as
outliers from severe or mild groups, respectively, as described in the
text. The solid lines, dotted lines, and dashed lines are the estimated
population regression lines for the young mild, older mild, and severe
groups, respectively.
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TABLE 1. CHARACTERISTICS OF STUDY GROUPS*
Younger Mild, 15–28 yr Older Mild,  29 yr
Severe, 8–25 yr of Age (n  256) of Age (n  304) of Age (n  242)
Characteristics at time of enrollment
Male, % 49.2 51.6 61.2§||
Age at enrollment 16.1  4.2 20.9  4.0‡ 37.9  5.3‡¶
Body mass index z-score 1.28  1.20 0.11  0.79‡ 0.39  1.08‡**
FEV1 (% pred) 46.9  17.3 91.7  17.9‡ 50.4  22.6¶††
FVC (% pred) 62.8  17.7 101.8  15.3‡ 71.0  21.6‡¶
FEF25–75 (% pred) 26.4  20.0 75.7  32.0‡ 25.7  23.0¶
FEV1/FVC ratio 0.65  0.12 0.78  0.09‡ 0.58  0.13‡¶
Number of PFTs per patient in previous 5 yr (range) 31.6  23.9 18.3  10.4 17.7  12.5
(3–191) (2–72)‡ (1–61)‡
Regressions of FEV1 (% pred) versus age†
FEV1 slope (%pred/yr) 3.6  2.2 1.1  1.8‡ 1.6  1.1‡**
FEV1 (% pred) at 15 yr of age 52.2  14.9 98.3  14.2‡ 86.7  12.6‡¶
FEV1 (% pred) at 20 yr of age 34.2  17.1 92.8  14.7‡ 78.7  12.1‡¶
Definition of abbreviation: PFT  pulmonary function test.
* Unless otherwise noted, table entries are mean  SD. Between-group comparisons made using 2 tests and pair-wise comparisons in a one-way analysis of variance.
† Mixed model estimates obtained from mixed linear model (see Appendix 1).
‡ Differs p  0.0001 from severe group.
§ Differs p  0.01 from severe group.
|| Differs p  0.05 from younger mild group.
¶ Differs p  0.0001 from younger mild group.
** Differs p  0.01 from younger mild group.
†† Differs p  0.05 from severe group.
from 0.5 for an index with no discriminating ability to 1.0 for
an index able to discriminate perfectly (i.e., where there is no
overlap in distribution between mild and severe groups).
One possible index of phenotype is the predicted probability
of being severe from the logistic regression of disease severity
on age and estimated FEV1 (% pred) at enrollment (i.e., the
method used to identify outliers in this study). However, because
the severity groups are defined by this method, it achieves perfect
separation by definition, and thus its performance cannot be
directly assessed in this study. We focus on other indices, such
as level of FEV1 at a fixed age, patient-specific slope of FEV1,
and estimated survival percentile. Results are presented based
on analysis of all 802 patients and for the subset of 553 patients
who had 5 yr of pulmonary function measurements with at least
one measurement in each year, to reduce the confounding influ-
ence of variability in length of follow-up (Table 2). Histograms
of selected indices by severity group are displayed in Figures
3A–3D.
FEV1 (% pred) at a fixed age. We examined the discriminating
ability of the patient’s estimated level of FEV1 (% pred) at 5,
10, 15, 20, and 25 yr of age, obtained using mixed model and
LS estimates of patient-specific slopes and FEV1 levels (Table 2).
Using mixed model estimates, optimal discrimination is achieved
using estimated FEV1 at around 20 yr of age (ROC area 
0.995). Estimated FEV1 at the younger ages of 5 and 10 yr, which
represent extrapolations back to young ages for many patients,
were not as accurate in distinguishing between mild and severe
groups. A histogram of the estimated FEV1 at 20 yr of age
(Figure 3A) indicates that there is little overlap between severe
and mild groups with respect to this measure. As indicated by
the ROC areas in Table 2, LS estimates of slopes or levels of
FEV1 (% pred) do not discriminate between groups as well as
the mixed model estimates do. It is well known that LS slopes
can be highly variable and imprecise for patients with few data
points over a short time period (17–20). When restricted to
subjects with 5 yr of data, the discriminating ability of LS esti-
mates improved, but mixed model estimates still outperformed
the LS estimates (Table 2).
Slope of FEV1 (% pred). Areas under the ROC curve were
0.821 and 0.703 for the mixed model and LS estimates of FEV1
slopes, respectively. Neither the mixed model (Figure 3B) nor
LS estimates of FEV1 slope (Figure 3C) were as good at discrimi-
nating between mild and severe patients as was the estimated
level of FEV1 at 15–25 yr of age.
Logistic regression on FEV1 slope and intercept. Because each
patient’s regression line is fully characterized by its intercept
and slope, another approach to developing a classification of mild
versus severe patients is to fit a logistic regression of phenotype
(severe vs. mild) using estimated FEV1 intercept at age 0 and
TABLE 2. DISCRIMINATION BETWEEN SEVERITY GROUPS
USING RECEIVER OPERATING CHARACTERISTIC CURVE
AREAS
Area under ROC Curve
Patients with
All Patients 5-yr Follow-up
Index (n  802) (n  553)
Mixed model estimates
FEV1, 5 yr of age 0.722 0.689
FEV1, 10 yr of age 0.880 0.860
FEV1, 15 yr of age 0.980 0.975
FEV1, 20 yr of age 0.995 0.994
FEV1, 25 yr of age 0.987 0.985
FEV1 slope 0.821 0.822
FEV1 slope and intercept* 0.995 0.994
Least-squares estimates
FEV1, 5 yr of age 0.594 0.597
FEV1, 10 yr of age 0.722 0.741
FEV1, 15 yr of age 0.835 0.869
FEV1, 20 yr of age 0.888 0.929
FEV1, 25 yr of age 0.891 0.935
FEV1 slope 0.703 0.744
FEV1 slope and intercept* 0.894 0.937
Predicted survival percentile 0.995 0.991
Definition of abbreviation: ROC  receiver operating characteristic.
* Logistic regression of severity group on patient-specific FEV1 slope and
intercept.
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Figure 3. Histograms of dis-
ease severity indices in severe
and mild groups. Histograms
are shown for (A ) FEV1 (% pred)
at 20 yr of age, (B ) slope of FEV1
(% pred), (C ) least-squares (LS)
slope of FEV1 (% pred), and (D )
survival percentile from infor-
mative censoring model. Esti-
mates in A and B are mixed
model (empirical Bayes) esti-
mates, using all available FEV1
measurements for each sub-
ject. The x axis scales differ be-
tween B and C, reflecting the
increased variability that is
present in the LS slopes. Three
outliers (two with slopes 
90%pred/yr and one with
slope 	 24%pred/yr) are ex-
cluded from C.
FEV1 slope as predictors (Appendix 2). When this approach
was used, the ROC area was 0.995 (Table 2). It can be shown
(Appendix 2) that the ROC area of this approach using the
intercept and slope is greater than or equal to the ROC area
based on using estimated FEV1 at any single fixed age. Also,
provided the logistic regression coefficient of the intercept is
nonzero (indicating that the FEV1 intercept contributes to pre-
diction in addition to the FEV1 slope), using the intercept and
slope to predict severity is equivalent to using the estimated
level of FEV1 at a single “optimal” age, estimated to be 19.6 yr
in the GMS study (Appendix 2). The optimal age of 19.6 yr
closely matches the empirically determined optimal age of 20
yr in Table 2, and the ROC area based on the FEV1 at age 19.6
(0.995) is identical to that obtained using the intercept and slope.
Predicted age at death obtained from a model relating survival
time to FEV1. A model relating survival to FEV1 (% pred), using
estimates of parameters obtained by fitting it to an external
dataset of 188 F508 homozygous patients with CF (2), was
applied to the GMS patient data to obtain a prediction of age
at death. The prediction for each individual is expressed as a
population percentile ranging from 0 to 1; thus, a predicted age
at death equal to the median for the F508 CF population would
result in the percentile equaling 0.50, and lower (higher) values
of the percentile represent worse (better) survival. Because the
original parameter estimates from this model were obtained by
fitting it to best yearly measures of FEV1, we also used best
yearly measures from the GMS data. The means and SDs of the
estimated percentiles of predicted age at death were 0.37  0.14,
0.81  0.09, and 0.78  0.06 for the severe, young mild, and
older mild groups, respectively. Figure 3D shows distributions
of the estimated survival percentiles. This approach provided
an ROC curve area of 0.994, providing essentially the same
discrimination between groups as the FEV1 (% pred) at the
optimal age of 19.6 yr.
Comparison of Estimates Obtained Using All versus Best
Yearly FEV1 Values
When analyzing longitudinal FEV1 data in patients with CF,
some authors (2) have analyzed the best (maximal) yearly mea-
surements of FEV1 on the grounds that these best yearly values
are more representative of the patient’s usual condition, whereas
the use of all available measurements may add variability and
bias due to the inclusion of subnormal values obtained during
acute illness episodes. On the other hand, subnormal FEV1 val-
ues obtained during acute illness may relate to severity status,
so it is not clear which approach is better. We therefore examined
properties of estimates of FEV1 slope and level at 20 yr of age,
derived using the best (maximal) yearly FEV1 per patient, and
compared findings with results based on using all available FEV1
values. Results are summarized in Table 3, where the comparison
is restricted to patients who had measurements of FEV1 in 5
consecutive years of data. For simplicity, we present comparisons
for LS estimates only.
The average of the residual mean square error (Table 3),
which is a measure of variability about each patient’s line, was
smaller when the best yearly FEV1 values were used. However,
despite the fact that within-patient variability was reduced when
using the best yearly FEV1 values, the magnitudes of the SDs
of LS slopes and estimates of FEV1 at 20 yr of age were compara-
ble for estimates based on all versus best yearly FEV1, and in
all cases the SDs were slightly larger when using the best yearly
FEV1. When examining the ability of LS estimates (intercept
and slope) to discriminate between severe and mild groups, the
ROC curve areas were 0.937 using all FEV1 values and 0.894
using the best yearly FEV1. Thus, in these data, analysis based
on all FEV1 values seemed to be preferable to analysis using
the best yearly FEV1.
When using the best yearly FEV1 as compared with all FEV1
values, the estimates of mean FEV1 at a fixed age are higher.
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TABLE 3. FEV1 PARAMETERS ESTIMATED USING ALL DATA VERSUS BEST YEARLY (MAXIMAL)
FEV1 VALUES, RESTRICTED TO THE SUBSET OF PATIENTS HAVING 5 CONSECUTIVE YEARS
OF DATA
FEV1 Data Used Severe (n  182) Young Mild (n  229) Older Mild (n  142)
FEV1 (% pred) at 20 yr of age All 35.2  22.9* 93.4  19.3 77.5  36.6
(least squares) Best yearly 44.4  29.1 101.6  20.0 80.0  39.0
FEV1 slope (%pred/yr) All 3.70  3.02 0.86  2.87 1.47  2.08
(least squares) Best yearly 3.73  3.58 0.41  3.00 1.42  2.26
Mean residual mean square error
about regression* All 8.03 7.76 5.10
Best yearly 5.90 5.49 3.85
* Table entries are the averages of the residual mean squares of the patient-specific least squares regressions of FEV1 (% pred)
on age in years.
This was more evident in the severe group than in the two mild
groups. Similar results were seen when examining mixed model
estimates (not shown). The group average slopes were generally
comparable whether best yearly or all FEV1 values were used.
An exception was that the average LS slope for the young mild
group based on best yearly FEV1 values was approximately 50%
less negative (less steep) as compared with the LS estimate using
all FEV1 values.
DISCUSSION
We demonstrate and empirically compare several approaches
used to phenotype patients with CF according to severity of
disease when longitudinal measures of lung function are avail-
able. The phenotypic summary measures derived from longitudi-
nal data examined in this article have the following advantages
over the use of a single FEV1 measurement: (1) they automati-
cally factor in the age of the patient, (2) summary measures
typically are more precise than single measurements, and (3)
they factor in the patient’s current level and his/her previous
rate of decline in FEV1. Possible uses of these phenotypic disease
severity indices in the context of gene modifier studies are (1)
to provide a rigorous method to quantify or estimate pulmonary
disease phenotype; (2) to define more extreme groups for com-
parison, such as the mildest versus the most severe of the pa-
tients; or (3) to use the index as a continuous measure of pheno-
type rather than dichotomizing patients into mild and severe
groups. Along these lines, in a replication study performed as
part of the GMS study (12), the estimated FEV1 (% pred) at age
20 was used as a continuous phenotype and also dichotomized
as  68% versus  68% to examine the association of severity
of pulmonary disease with the TGFB1 codon 10 genotype.
The two approaches that best discriminated between severe
and mild groups as defined in the GMS patients were (1) logistic
regression using intercept and slope of FEV1 (% pred; mixed
model estimates) as predictors and (2) the predicted survival
age percentile. ROC curve areas for these two approaches were
essentially the same (0.995 and 0.994, respectively). Although
we used intercept at birth and slope of FEV1 in the model, the
use of estimated FEV1 at any other age along with slope provides
an equivalent predictive model. We show that prediction of
severity group using the logistic regression on slope and intercept
is equivalent to using estimated FEV1 at 19.6 yr of age as a single
summary index and that the estimated level of FEV1 at this
“optimal” age outperforms FEV1 estimated at other ages. Thus,
the first approach can be simplified by using estimated FEV1 at
20 yr of age as a single summary index. An advantage of this
approach is its simplicity. A potential drawback is that the mixed
model estimates of FEV1 at a fixed age and slope are not indepen-
dent of the group to which the subject was initially assigned
because the mixed model estimates are “shrunken” toward the
mean of the group to which the patient was initially assigned.
Although the survival percentile had the disadvantage of being
more complex to calculate, it has several advantages: (1) it is
estimated using only the subject’s actual FEV1 data and attained
age and is thus independent of the initial group assignment and
(2) it is calculated using parameters estimated externally to the
sample of 802 subjects. The congruence of two very different
methods (logistic regression based on slope and intercept, and
survival percentile) in predicting severity was encouraging in the
GMS and supports the validity of using either measure as a
continuous severity measure.
Other summary indices, such as estimated level of FEV1 (%
pred) at 5, 10, 15, and 25 yr of age and FEV1 slope, did not
discriminate between severity groups as well as estimated FEV1
at 20 yr of age or the estimated survival age percentile. The
results indicate that the estimated slope of FEV1 (% pred),
whether estimated using the mixed model or LS, does not dis-
criminate between mild and severe groups nearly as well as the
patient’s level of FEV1 (% pred) at 20 yr of age, which is a
function of the patient’s estimated level of FEV1 (intercept)
and the slope. In an analysis using mixed models to compare
intercepts and rates of decline in FEV1 (% pred) of patients
with CF, grouped by age at death, Corey and colleagues (3)
similarly showed that patients who died earlier had lower inter-
cepts and more negative slopes of FEV1 (% pred), supporting
the notion that severity is manifested through the initial level
and the slope of FEV1 (% pred).
The GMS sought to avoid the limitations of phenotyping
on the basis of a single FEV1 measurement; thus, longitudinal
spirometry data were collected for the previous 5 yr on each
subject, with the goal of better characterizing each patient’s
status using all the data. Study design and enrollment criteria
were based on a number of clinical and practical considerations
related to this approach, some of which are reinforced by these
results. Only patients who had survived to the age of 8 yr were
enrolled because of the need to obtain multiple measures of
spirometry in previous years, with the expectation that many
8-yr–old patients would have 3 yr of data (i.e., at age 6–8 yr).
Patients could be classified as severe at ages as young as 8 yr
because having a low FEV1 at a very young age is predictive of
poor outcome (2, 3). The severe group extended only up to
25 yr of age because patients older than 25 yr would not be in
the “worst” quartile of their birth cohort by virtue of surviving
beyond 25 yr of age. For analogous reasons, patients who reached
34 yr of age were considered to have mild disease (i.e., were in
the “best” quartile of their birth cohort) regardless of their level
of pulmonary function because of their survival status. Finally,
results presented here show that an individual patient’s level of
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FEV1 at younger than 10 yr is not as reliable a predictor of
severity as is the level at approximately 15 to 20 yr of age. The
FEV1 level at 20 yr of age reflects the patient’s initial level
and their rate of decline and can be reliably estimated only by
following the patient to that age or by obtaining several years
of data on younger patients. Similarly, Schluchter and colleagues
(2) reported that, based on a joint model relating survival to
FEV1 longitudinal data in patients with CF, the highest correla-
tion between age at death and the patient’s level of FEV1
(% pred) occurs in the range of 15 to 20 yr of age. For these
reasons, the GMS did not attempt to classify a patient as “mild”
before the age of 15 yr.
The mixed model estimates we evaluated were obtained from
a model with severity group included in the model; thus, the
intercept and slope estimates for each patient are shrunken to-
ward the group mean to which the patient is initially assigned
rather than toward the overall mean. An implication is that the
estimate for an individual patient is influenced to some extent
by the group to which the patient was initially assigned, particu-
larly for patients with few points over a short age range. Thus,
the mixed model estimates may seem to be somewhat better
discriminators between mild and severe patients than they actu-
ally are, particularly when patients with short follow-up times
are included. For example, among patients with FEV1 measure-
ments in five consecutive years of follow-up, the area under the
ROC curve for a logistic regression using the individual estimates
of slope and intercept obtained under a mixed model not includ-
ing group as a fixed effect was 0.969, compared with an area of
0.994 for estimates obtained from a model with group included.
Mekus and colleagues (21) describe an alternative method
for classifying severity of pulmonary disease in patients with
CF by calculating age-specific percentiles of FEV1 (% pred) in
patients with CF, as determined from analysis of data in the
European CF Registry. Using equations provided to us
(F. Mekus-Stanke, personal communication), we calculated the
percentile of FEV1 (% pred) for GMS patients 30 yr of age or
younger, the age range for which the calculations apply. Because
this approach was originally developed using only a single FEV1,
we adapted it to our longitudinal data by using the mixed model
estimate of level of FEV1 (% pred) at the patient’s final age and
excluded patients older than 30 yr. The estimated ROC area for
this index was 1.00, indicating complete separation between the
groups. This is not unexpected because the mild and severe
groups in the GMS study, by definition, show complete separa-
tion based on FEV1 (% pred) at any given age, which is what
the Mekus equation is based on. A possible drawback of the
Mekus approach is that it does not consider survival. For exam-
ple, two patients, 8 and 30 yr of age, who each have FEV1 at the
50th percentile of their surviving cohorts, would be considered
equivalent in severity, although the 30-yr-old patient has milder
disease, when factoring in survival. Recently, Kulich and col-
leagues (22) published age- and gender-specific percentiles of
FEV1 (% pred) for patients with CF using data from the U.S.
CF Foundation Patient Registry (1994–2001) for ages 6–40 yr
in graphical form, which would allow similar percentiles to be
calculated using data from patients with CF in the United States.
A limitation of the approach we have taken is that there is
some circularity involved in defining severity and then comparing
candidate severity measures against the groups so defined. The
way severe and mild groups were initially defined precluded a
“fair” comparison of the discriminating ability of the logistic
regression using last predicted FEV1% predicted and age as pre-
dictors, or of the Mekus approach, both of which result in 100%
discrimination between groups in this dataset. However, the
survival prediction, which is independent of the initial group
assignment and estimated based on externally estimated parame-
ters, yielded similar discrimination to the optimal approach using
the patient’s slope and intercept in a logistic regression model.
In conclusion, we have described an approach for enrolling
and phenotyping patients with CF with severe and mild disease.
Patients were enrolled initially based on age-specific cutoffs for
their current FEV1, and this classification of disease severity was
confirmed after analysis of their longitudinal data in the 5 yr
preceding enrollment. Only 18 of 820 (2%) of patients were
deemed to be misclassified according to extremes of phenotype
(severe vs. mild) based on the single initial FEV1, when all
longitudinal data were examined. Subsequent analyses suggest
that the estimated FEV1 (% pred) at 20 yr of age, calculated
from longitudinal data, is an accurate discriminator between
patients with severe and mild disease and can be linked to long-
term outcome (i.e., duration of survival), which is the most im-
portant phenotypic outcome measure for testing the association
of gene modifiers. Estimates of FEV1 (% pred) at 20 yr of age
from a longitudinal study may also be useful as a continuous
index of disease severity, as evidenced by the approach recently
used in the GMS (12).
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APPENDIX 1. MIXED EFFECTS MODEL
Let yij be the jth measurement of FEV1 (% pred) obtained on
the ith subject, for i  1, … , ni. Define the group indicator vari-
ables G1i  1 if subject i is in the older mild group and 0 otherwise,
and G2i  1 if subject i is in the severe group and 0 otherwise.




2G2i  bi0)  (0  1G1i  2G2i  bi1)  eij
where the 
’s and ’s, . . . are unknown fixed effects parameters
of the intercepts and slopes, bi0 and bi1 are random effects for
the intercept and slope, and eij are independent normal errors
with mean 0 and variance 2. In this model, the mean intercepts





2 for the young mild, older
mild, and severe groups, respectively, and mean slopes are 0,
0  1, and 0  2 for the same three respective groups. Mixed
model estimates of individual slopes and intercepts (also called
empirical Bayes estimates and Best Linear Unbiased Estimates)
are obtained using SAS Proc Mixed as described in Littell and
colleagues (23). Estimated mean intercepts ( SE) for the young
mild, older mild, and severe groups were 114.8  2.7, 110.7 
4.1, and 106.2  2.7, respectively, and estimated mean slopes
were 1.10  0.14, 1.60  0.16, and 3.60  0.15, respectively.
Estimated variance components were: Var(intercept)  1,485.0,
Var(slope)  4.017, Cov(intercept, slope)  70.2, and ̂2 
63.3.
APPENDIX 2. LOGISTIC REGRESSION OF SEVERITY
GROUP ON FEV1 INTERCEPT AND SLOPE
A logistic regression of severity (severe vs. mild) on the patient-
specific estimated FEV1 intercept (at age 0 yr) and slope can be
expressed as Logit (P[severe])  1  2(intercept)  3(slope).
By rearranging the right-hand side of the equation, for given
values of the parameters 1, 2, and 3 (provided 2  0), it can be
expressed equivalently as: Logit P(severe)  1  2{intercept 
3/2 (slope)}  1  2(estimated FEV1% predicted at age 3/2).
Thus, when this model holds and 2  0, it implies that an
equivalent prediction is obtained using the single predictor de-
fined as the patient’s estimated FEV1% predicted at age 3/2.
That is, the ratio of parameters 3/2 estimates the optimal age
for predicting severity based on the level of FEV1% predicted at
that age.
This model was fit to the GMS data, yielding estimates (SEs)
of the parameters: ̂1  16.966 (2.093), ̂2  0.288 (0.033), and
̂3  5.640 (0.612). The area under the ROC curve was 0.995.
The optimal age was ̂3/̂2  19.6 y, indicating that an equivalent
predictive model is obtained by using the predicted FEV1% pre-
dicted at age 19.6 yr as a single predictor in a logistic model.
